Outsourced Pharma Capacity Update Videos - Small Molecule

  1. SK Pharmteco Capabilities Update March 2026: Small Molecule Drug Substance 3/11/2026

    Join Frank Mueller, Executive Director of Business Development, for an overview of our capabilities and global capacity spanning North America, Europe, and Asia.

  2. Novartis Capabilities Update March 2026: Small Molecule Drug Substance 3/11/2026

    Driven by a strong commitment to quality, compliance, and operational excellence, our teams deliver reliable and scalable manufacturing solutions tailored to each partner’s unique requirements.

  3. Ropack Pharma Solutions Capacity Update October 2025: Small Molecule 10/16/2025

    For clinical trials, we provide full support from warehousing to returns. Join Ropack's Head of Commercial, Chris Vounasis, for a presentation on our technologies and 2025–2026 capacity.

  4. Pfizer CentreOne Oral Solids Capacity Update October 2025: Small Molecule 10/16/2025

    With specialized technologies like laser drilling, multilayer coating, and orally disintegrating tablets, our state-of-the-art facilities provide the precise infrastructure to support your most demanding OSD requirements.

  5. Lonza Capacity Update October 2025: Small Molecule 10/16/2025

    Get an overview of our AI-assisted early phase toolkit, which combines predictive modeling, formulation screening, and data-driven insights to accelerate molecule progression.

  6. Douglas CDMO Capacity Update October 2025: Small Molecule 10/16/2025

    Choose an experienced CDMO specializing in high-potency softgels and liquids to ensure high-quality products, responsive service, and reliable solutions across complex therapeutic areas.

  7. Alcami Capacity Update October 2025: Small Molecule 10/16/2025

    Partner with a flexible, high-quality manufacturing expert to accelerate your bench-to-clinic journey, strengthen supply chain, and ensure seamless commercialization of oral solid dose therapies.

  8. Upperton Pharma Solutions Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form 7/29/2025

    Ian Lafferty, CTO, and Josh Moule, Business Development Manager, talk through Upperton’s capabilities, project management approach and provide a virtual tour of their 60,000 sq. ft development and manufacturing facility.

  9. Quotient Sciences Capacity Update July 2025 7/29/2025

    Explore how expedited review pathways can be strategically used to accelerate development while mitigating CMC risks.

  10. PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form 7/29/2025

    Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.